Summary Prothena Corp Plc (Prothena) is a biotechnology company that discovers, develops and markets novel antibodies that are indicated for the treatment of diseases associated with amyloid or cell adhesion. The company develops monoclonal antibodies directed specifically at disease-causing proteins. Its pipeline products comprise PRX002, indicated for the treatment of Parkinson’s disease; NEOD001, indicated for the treatment of primary systemic amyloidosis; PRX003, indicated for the treatme...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.